Biomedical subjects
E Fojt
Publications and source records attributed to E Fojt.
Hepatic function during considerable sport exercise in the light of the bromsulphthalein (BSP) test.
Explore the source record for details and available documents.
[Effect of physical effort on trained and untrained rats kept on different diets].
Explore the source record for details and available documents.
Urinary and serum trypsin inhibitors in viral hepatitis.
Explore the source record for details and available documents.
Liver function after exhaustive physical effort.
Explore the source record for details and available documents.
[Liver activity during considerable exertion in sports in the light of the bromosulphophthalein test].
Explore the source record for details and available documents.
[Liver function during strenous physical exertion].
Explore the source record for details and available documents.
The effect of corticotherapy on fibrinolysis in viral hepatitis.
Explore the source record for details and available documents.
[Effect of certain psychotropic drugs on the function of sweat glands in a hot environment].
Explore the source record for details and available documents.
The influence of corticotherapy on the blood proteolytic activity in viral hepatitis.
Explore the source record for details and available documents.
[Mild lesion of the liver caused by metanabol in 3 sportsmen performing weight lifting].
Explore the source record for details and available documents.
[Mitral valve prolapse in sportsmen].
Explore the source record for details and available documents.
[Aztreonam--new antibiotic for treating infections caused by gram-negative aerobic bacteria].
Aztreonam is the first synthetic monobactam used in practical medicine. It is effective in Gram-negative aerobe infections. It inhibits the growth of most Enterobacteriaceae in concentrations below 2 mg/ml, and of Pseudomonas aeruginosa below 16 mg/ml. It shows a widespread, distribution achieving effective therapeutic concentration there, where infections are seen most frequently. The half-life is from 1.6 to 2.0 hours. It can be administered to patients every 8 and 12 hours in single parenteral doses of 0.5, 1.0, and 2.0 g. Aztreonam is a non-toxic antibiotic, a weak hapten with slight allergenicity. It has found therapeutic use together with the antibiotics directed against aerobic and anaerobic bacterial Gram-positive flora, and it is used in the therapy directed against infections with Gram-negative aerobes. It is an effective antibiotic in nosocomial infections, in oncological patients with neutropenia, and in elderly patients.